Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 11/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6590160 | 0.91 | GABRG2 (0.35) | GABRG2GABRB3GABRA5CHRM2CHRM4 | |
| SCHEMBL6588897 | 0.74 | GABRG2 (0.31) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL6591154 | 0.74 | TRPV3 (0.34) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL6590303 | 0.72 | GABRG2 (0.31) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL14765171 | 0.71 | NR1H2 (0.39) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL10064601 | 0.69 | GABRG2 (0.72) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL2310246 | 0.68 | CHRM2 (0.34) | GABRG2GABRB3GABRA5CHRM2CHRM4 | |
| SCHEMBL23723352 | 0.68 | CDK1 (0.47) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL2314326 | 0.68 | NR1H2 (0.35) | GABRG2GABRB3GABRA5GABRA1GABRA2 | |
| SCHEMBL28632028 | 0.67 | GABRG2 (0.65) | GABRG2GABRB3GABRA5GABRA1GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358180-B1 | NAPHTHOSTYRIL DERIVATIVES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | HOFFMANN LA ROCHE (CH) | 2004-12-01 | — | — | EP | claimed |
| US-6504034-B2 | Cell antiproliferative agents; anticancer agents | HOFFMANN-LA ROCHE INC. | 2003-01-07 | — | — | US | claimed |
| US-20020147343-A1 | Naphthostyrils | CHEN YI (US) | 2002-10-10 | — | — | US | claimed |
| EP-1358180-B1 | NAPHTHOSTYRIL DERIVATIVES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | HOFFMANN LA ROCHE (CH) | 2004-12-01 | — | — | EP | disclosed |
| US-6531598-B1 | Naphthostyrils | HOFFMANN-LA ROCHE INC. | 2003-03-11 | — | — | US | disclosed |
| US-6504034-B2 | Cell antiproliferative agents; anticancer agents | HOFFMANN-LA ROCHE INC. | 2003-01-07 | — | — | US | disclosed |
| US-20020147343-A1 | Naphthostyrils | CHEN YI (US) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147343-A1 | Naphthostyrils | CCNI, CDKL1, CDK2 | GABRG2 4536/4885GABRB3 4677/4885GABRA5 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.